Skip to content

Released May 10, 2024, before the open

10-Q filed May 10, 2024, 40 days after period end · 0001558370-24-007695

Q1 2024 · 10-Q
Revenue$3.75M−60.9% vs Q1 2023−64.3% vs Q4 2023
Net Income-$4.60MN/M vs Q1 2023N/M vs Q4 2023
EPS Diluted-$0.06N/M vs Q1 2023no prior Q4 2023 on file
Operating Income-$4,856,000N/M
Operating Cash Flow$4,188,000N/M
Free Cash Flowderived$3,590,000N/M
Margins · derived
Operating margin-129.6%−103.9 pt vs Q1 2023
Net margin-122.6%−89.9 pt vs Q1 2023

What the release said

The release

Same quarter

MetricQ1 2024Q1 2023Q1 2022Q1 2021
Revenue$3.75M$9.59M$16.09M$11.32M
Net Income-$4.60M-$3.13M-$2.29M-$5.48M
EPS Diluted-$0.06-$0.05-$0.05-$0.14

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR